MMI Co-Founder, John Hipp, PhD. selected as Guest Editor for Special Issue of Bioengineering!
Imaging plays a key role in patient selection for GAE treatment.
Onboarding an expert-imaging group in your clinical trials is essential for success!
Dr. Mark Schweitzer discusses a return to low-field MRI spurred on by energy demands and tech advances.
Radiographic spine fusion assessment is complicated by a lack of standardized criteria, highlighting the need for imaging expertise during clinical trials.
Dr. Mark Schweitzer, MD, expounds on design and reporting considerations for imaging assessments in research publications.
Insights from the 2022 OARSI Clinical Trials Symposium
In a research letter in Spine, MMI collaborated with researchers to investigate the SPSI as an objective measure of instability in lumbar stenosis patients with degenerative spondylolisthesis.
Since 2000, the FDA has explicitly described the importance of radiographic evaluation in spinal studies in primary and secondary endpoints.
FDA recommends using imaging of the sinuses as a secondary efficacy endpoint for drugs being developed to treat chronic rhinosinusitis with nasal polyps (CRSwNP).
Semi-automated quantitative measurements of sinus inflammation from 3D CT imaging correlate well with clinical outcomes.
Facing an aging population and unprecedented scrutiny over treatment costs, clinical trials that seek to improve treatment of late-stage conditions and diseases such as osteoarthritis are set to make a significant impact.
A new study finds that small brain lesions previously thought to be insignificant are associated with heightened risk of stroke, increasing the importance of utilizing the very best medical imaging technology and experienced readers.
